Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02260609 · ClinicalTrials.gov registry record · Phase 4
GrafixCORE®: Open-Label Study to Evaluate the Safety and Efficacy of GrafixCORE® for Complex Diabetic Foot Wounds
A Phase 4 study, sponsored by Osiris Therapeutics.
- Completed
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
NCT02260609 is a Phase 4 study that has completed, run by Osiris Therapeutics. The registered enrollment target is 31 participants.
The verdict
NCT02260609, a Phase 4 study, has completed, sponsored by Osiris Therapeutics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
Study Summary
A multicenter, open-label, single-arm study to evaluate the safety and efficacy of GrafixCORE® for the treatment of complex diabetic foot wounds with exposed tendon and/or bone.
Interventions
- OTHER Grafix®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2014-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02260609
The ClinicalTrials.gov registry entry for NCT02260609 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Osiris Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Grafix® is the first listed.
NCT02260609 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02260609 about?
NCT02260609 is a clinical study titled "GrafixCORE®: Open-Label Study to Evaluate the Safety and Efficacy of GrafixCORE® for Complex Diabetic Foot Wounds". A multicenter, open-label, single-arm study to evaluate the safety and efficacy of GrafixCORE® for the treatment of complex diabetic foot wounds with exposed tendon and/or bone.
What is the current status of trial NCT02260609?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2014-10.
What interventions are being tested in trial NCT02260609?
The interventions under investigation include: Grafix® (OTHER).
Who is sponsoring clinical trial NCT02260609?
This trial is sponsored by Osiris Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.